Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M208Revenue $M0.0Net Margin (%)-353,077.8Z-Score34.6
Enterprise Value $M155EPS $-1.3Operating Margin %-353,077.8F-Score3
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-353,077.8Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %-16.1Quick Ratio17.9Cash flow > EarningsY
Price/Sales19,7995-y EBITDA Growth Rate %-21.4Current Ratio17.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-44.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-46.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M23.1ROI % (ttm)-56.0Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 8.56-42%New holding, 1000000 sh.1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
RPRX John Paulson 2014-09-301,000,0004.330.04New Buy
Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-4.25view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-4.14view
Masterson Nola EDirector 2014-09-15Buy200$14.34-37.1view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-34.87view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-35.15view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-39.75view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-49.61view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-49.97view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-62.05view
Anderson KatherineCFO 2013-02-01Buy1,000$11.89-24.14view

Press Releases about RPRX :

    Quarterly/Annual Reports about RPRX:

    News about RPRX:

    Articles On GuruFocus.com
    comment on RPRX Mar 06 2013 
    Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
    promotes testosteron Jun 22 2011 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
    Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

    More From Other Websites
    REPROS THERAPEUTICS INC. Financials Nov 15 2014
    10-Q for Repros Therapeutics, Inc. Nov 12 2014
    Brean Capital Sees No Surprises In 3Q14 Report For Repros Therapeutics Nov 11 2014
    Repros Soars on Positive FDA Meeting Regarding Androxa Nov 10 2014
    Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results Nov 10 2014
    Repros Therapeutics posts 3Q loss Nov 10 2014
    Repros Therapeutics posts 3Q loss Nov 10 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 10 2014
    Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results Nov 10 2014
    Q3 2014 Repros Therapeutics Inc Earnings Release - Before Market Open Nov 10 2014
    Another lackluster session for major equities Nov 07 2014
    Sears Soars Nearly +40% As REIT News Boosts Confidence Nov 07 2014
    Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal Nov 07 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events Nov 06 2014
    Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing Nov 06 2014
    Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing Nov 06 2014
    Will Repros (RPRX) Miss Estimates This Earnings Season? Nov 05 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 31 2014
    Repros to Webcast Investor and Analyst Day on October 31st Oct 27 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 27 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK